Originally published as JHC exPRESS on May 3, 2007. doi:10.1369/jhc.6A7119.2007
Volume 55 (9): 891-898, 2007 Copyright ©The Histochemical Society, Inc. Immunohistochemical Analysis of Regulatory T Cell Markers FOXP3 and GITR on CD4+CD25+ T Cells in Normal Skin and Inflammatory Dermatoses
Departments of Pathology (OJdB,CMvdL,PT,ACvdW) and Dermatology (MBMT), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Correspondence to: Dr. O.J. de Boer, Department of Pathology, Academic Medical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands. E-mail: o.j.deboer{at}amc.uva.nl
Regulatory T cells (Treg) are a subset of T lymphocytes that play a central role in immunologic tolerance and in the termination of immune responses. The identification of these cells in normal and inflammatory conditions may contribute to a better understanding of underlying pathology. We investigated the expression of FOXP3 and GITR in normal skin and in a panel of different inflammatory dermatoses. Immunohistochemical double stainings in skin tissue sections revealed that FOXP3 and GITR were almost exclusively present on T cells that express both CD4 and CD25. Further, immunohistochemical double staining, as well as fluorescence-activated cell sorter analysis, on peripheral blood T cells showed that most FOXP3+ cells expressed GITR and vice versa, whereas a minority were single-positive for these markers. The mean frequency of FOXP3+ T cells in spongiotic dermatitis, psoriasis, and lichen planus was in the same range (25–29%), but the frequency of these cells in leishmaniasis appeared to be lower ( 15%), although this was not statistically significant. The mean frequency of GITR+ T cells was fairly similar in all conditions studied (14–20%). Normal human skin also contained FOXP3+ and GITR+ cells in the same frequency range as in diseased skin, but the absolute numbers were, of course, much lower. In conclusion, frequencies of FOXP3+ and GITR+ T cells were similar in all inflammatory skin diseases studied and normal skin, despite the well-known differences among the inflammatory conditions under investigation. (J Histochem Cytochem 55:891–898, 2007)
Key Words: regulatory T cells inflammation dermatoses immunohistochemistry spectral imaging
REGULATORY T CELLS (Treg), formerly called suppressor T cells, are a subset of T lymphocytes that play a central role in inducing and maintaining immunologic tolerance and in the termination of immune responses. Deficiency or dysfunction of these cells may lead to autoimmunity or aggravated pathogen-induced inflammation (Maggi et al. 2005
The functional activity of effector T cells and Treg must be in proper balance to achieve adequate immune responses. Consequently, abnormalities in number and function of Treg disturb this control mechanism of immune regulation and may contribute to the pathogenesis of a given disease. Thus far, studies on human Treg have mostly been carried out on the CD4+CD25high subset of T cells from peripheral blood samples obtained from either healthy or diseased individuals. Little is known about the presence or distribution of Treg in normal and diseased human tissue because of a lack of specific markers. CD25 is strongly and constitutively expressed by Treg, but identification of CD4+CD25+ cells is not an option, because recently activated T cells also express CD25. A suitable marker that has been put forward to identify Treg is the transcription factor FOXP3, a member of the forkhead winged helix protein family of transcription factors (Fontenot et al. 2003 At present, little is known about the distribution or frequency of Treg in normal and diseased skin. Therefore, we studied FOXP3- and GITR-positive T cells in normal skin and a panel of inflammatory skin disorders. In the first part of the study, we evaluated the coexpression of FOXP3, GITR, CD4, and CD25, using an immunohistochemical double-staining approach. For optimal evaluation of double staining, we used spectral imaging, a new and powerful computer-assisted optical technique that improves perceptibility of each individual color in immune double stains. In the second part of the study, we investigated the frequency of the putative Treg markers FOXP3 and GITR in normal skin as well as in the lesional skin of several different types of inflammatory skin diseases, including hypersensitivity reaction of the skin (spongiotic dermatitis), infectious skin disease (leishmaniasis), psoriasis, and lichen planus.
Flow Cytometry Mononuclear cells were purified from peripheral blood from healthy donors using Lymphoprep (1.077 g/ml; Axis-Shield Poc AS, Oslo, Norway) density gradient centrifugation. Nonspecific binding of antibodies was prevented by incubating the cells in phosphate-buffered saline containing heat-inactivated 10% normal human serum, 10% fetal bovine serum, and 0.1% sodium azide. Cells were indirectly stained with anti-GITR extracellular domain antibody (clone 110416; R & D Systems Europe Ltd, Abingdon, UK) and FITC-conjugated F(ab')2 fragments of goat anti-mouse IgG and IgM (Jackson ImmunoResearch Laboratories, Inc.; West Grove, PA). Then cells were incubated for 10 min at 4C with normal mouse serum (Dako; Glostrup, Denmark) followed by PerCP Cy5.5-conjugated anti-CD4 (Becton Dickinson; Mountain View, CA) and allophycocyanin-conjugated anti-CD25 (eBioscience; San Diego, CA). Finally, cells were intracellularly stained with phycoerythrin-conjugated anti-FOXP3 (clone PCH101; eBioscience) according to the manufacturer's protocol, using fixation and permeabilization buffers from the same provider. Isotype-matched antibodies were used as controls to adjust the instrument settings of the flow cytometer. Flow cytometry was conducted on a FACSCalibur (Becton Dickinson) and analyzed by WinMDI 2.8 software (internet freeware).
Tissue Specimens
Single Staining
Double Staining A double staining combination FOXP3–GITR was performed on the formalin-fixed and paraffin-embedded skin samples. The following sequence of steps was applied: blocking of endogenous peroxidase activity using methanol and peroxide; heat-induced antigen retrieval using Tris-HCl/EDTA, pH 9.0; serum-free protein block; a cocktail of FOXP3 antibody 236A/E7 and GITR antibody (goat derived); unlabeled rabbit anti-goat immunoglobulin (Dako); EnVision+ anti-rabbit/HRP (Dako); peroxidase activity visualization with DAB+ kit; normal rabbit serum; AP-conjugated rabbit anti-mouse immunoglobulin (Dako); and finally, visualization of AP activity with LPR. Double staining combinations CD25–GITR and CD4–GITR were performed on acetone-fixed cryostat tissue sections. The following sequence of steps was applied: blocking of endogenous peroxidase activity using sodium azide (0.1%) and peroxide (0.3%) in TBS; serum-free protein block; anti-GITR overnight at 4C; biotinylated swine anti-goat immunoglobulin (BioSource; Camarillo, CA); AP-conjugated streptavidin (Dako); AP activity visualization with LPR; normal goat serum; CD4 or CD25 antibody; EnVision+ anti-mouse/HRP polymer; peroxidase activity visualization with DAB+. Negative and "half" (omission of one antibody of the combination) double-staining control experiments were performed with matched species or mouse isotype control reagents using similar immunoglobulin concentrations.
Spectral Imaging
Quantification
Statistical Analysis
Expression of FOXP3 and GITR by Peripheral Blood T Cells We first estimated the association of Treg markers FOXP3 and GITR using the well-defined and easily accessible CD4+CD25high Treg subset in peripheral blood. One representative example out of four separate experiments is illustrated in Figure 1 . On the basis of CD4 expression and side scatter pattern, CD4+ lymphocytes were selected (Figure 1A) for further analysis. CD4+CD25high, CD4+25low, and CD4+CD25neg subsets were gated (Figure 2B ) according to the original report on the identification of human Treg by Baecher-Allan et al. (2001) 75%) did not express FOXP3, but 20% of this latter population did show a weak expression of GITR. The second population of T cells in the CD4+CD25low subset was FOXP3+, and 40% of these cells also expressed GITR. Finally, the expression of FOXP3 and GITR in the CD4+CD25neg subset was negligible (Figure 1E). These results confirm data from the literature that FOXP3 is a good indicator for CD4+CD25high Treg. Furthermore, it shows that the majority of the CD4+CD25+FOXP3+ T cells coexpresses GITR and that a minor proportion is GITRneg.
Phenotype of FOXP3- and GITR-positive Cells in Inflammatory Dermatoses To get a clear view of the phenotype of FOXP3+ and GITR+ cells in situ, we performed immunohistochemical double staining of FOXP3 with GITR, CD4, or CD25 and GITR with CD4 or CD25. Double staining was performed on sections from patients with psoriasis, lichen planus, and normal skin. Representative examples are illustrated in Figure 2, which shows sections from psoriatic lesional skin. FOXP3+ T cells were almost always CD4+CD25+, and the majority also expressed GITR. However, FOXP3+GITRneg cells were present ( 10%) in all specimens studied, and, very occasionally, CD25negFOXP3+ cells were encountered (<1%). GITR expression was observed exclusively in coexistence with cells that also express CD4 and CD25 (see Figures 2N and 2P, as well as Figures 2R and 2T, which are identical, implying complete overlap). Approximately 25% of the GITR+ cells showed no colocalization with FOXP3.
Frequency of FOXP3- and GITR-positive Cells in Inflammatory Dermatoses
Approximately 20% of the CD3+ T cells in normal human skin expressed GITR (Figure 4B). The variation of GITR+ cells in the different skin diseases was smaller than observed with FOXP3. No significant differences in frequency of GITR+ cells between any of the skin diseases and normal skin could be detected.
There is mounting interest in the role of Treg in autoimmunity and chronic inflammatory diseases. In the current literature, most studies have investigated the functional properties of peripheral blood–derived Treg in vitro and the role of Treg in different types of animal models of inflammation or autoimmunity (Baecher-Allan and Hafler 2004
In the present study, we investigated the expression of two markers for Treg, FOXP3 and GITR, in relation with CD4 and CD25 in a panel of normal and diseased skin specimens. In agreement with the current literature, we confirmed the association of FOXP3 and GITR with the CD4+CD25high T lymphocytes in the peripheral blood of normal healthy individuals (McHugh et al. 2002
In the second part of the study, we compared the frequency of Treg between normal skin and different types of inflammatory skin diseases. On average, the frequency of FOXP3+ T cells was similar in normal skin, spongiotic dermatitis, psoriasis, and lichen planus but was, although not significantly so, lower in leishmaniasis. However, in this respect, it is important to note that there was considerable variation of FOXP3+ cells among the specimens of each group. Moreover, these frequencies were not only variable in pathologic skin, which could be a result of the stage of the inflammatory process, but in normal human skin also, a large variation in the frequency of FOXP3+ T cells was found among the different patients. Still, on average, it appears that these different pathologic conditions of the skin are not related to an abnormal (local) frequency of Treg. This does not necessarily mean that Treg are not involved in the pathogenesis of any of the investigated diseases. For instance, in psoriasis, it has been observed that it is not the frequency but rather the functional suppressor potential of Treg in peripheral blood and dermis of psoriasis patients that is decreased, which may contribute to the unrestrained hyperproliferation/activation of effector T cells in psoriatic lesional skin (Sugiyama et al. 2005
Verhagen et al. (2006) In summary, naturally occurring Treg are easily detectable in tissue sections from normal as well as diseased skin specimens by the markers FOXP3 and, to a lesser extent, with GITR. Although the frequency of these cells may vary considerably, the mean frequency of these cells seems to be fairly steady irrespective of skin condition.
The authors thank Al Floyd (CRi; Woburn, MA) for assistance with spectral imaging experiments and Mrs. H. Ploegmakers for technical assistance.
Received for publication October 18, 2006; accepted April 9, 2007
Bacchetta R, Gregori S, Roncarolo MG (2005) CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmun Rev 4:491–496[CrossRef][Medline] Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25high regulatory cells in human peripheral blood. J Immunol 167:1245–1253 Baecher-Allan C, Hafler DA (2004) Suppressor T cells in human diseases. J Exp Med 200:273–276 Bluestone JA, Abbas AK (2003) Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253–257[CrossRef][Medline] Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330–336[CrossRef][Medline] Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061 Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4:337–342[CrossRef][Medline] Levenson RM, Mansfield JR (2006) Multispectral imaging in biology and medicine: slices of life. Cytometry A 69:748–758[Medline] Londei M (2005) Role of regulatory T cells in experimental arthritis and implications for clinical use. Arthritis Res Ther 7:118–120[CrossRef][Medline] Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F (2005) Thymic regulatory T cells. Autoimmun Rev 4:579–586[CrossRef][Medline] McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC (2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16:311–323[CrossRef][Medline] Nielsen J, Holm T, Claesson M (2004) CD4+CD25+ regulatory T cells: II. Origin, disease models and clinical aspects. APMIS 112:642–650[CrossRef][Medline] Pillai V, Ortega SB, Wang CK, Karandikar NJ (2007) Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 123:18–29[CrossRef][Medline] Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, Pratap S, et al. (2005) Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. Eur J Immunol 35:1681–1691[CrossRef][Medline] Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352[CrossRef][Medline] Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135–142[CrossRef][Medline] Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M, et al. (2004) Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 173:5008–5020 Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, McCormick TS, et al. (2005) Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174:164–173 Verhagen J, Akdis M, Traidl-Hoffmann C, Schmid-Grendelmeier P, Hijnen D, Knol EF, Behrendt H, et al. (2006) Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 117:176–183[CrossRef][Medline] Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF (2003) Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 112:1437–1443[CrossRef][Medline] Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, Maeda M, et al. (2004) Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 16:1643–1656
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||